Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits
Media formats available:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
- CDMC 2018: Shifting gears in the management of diabetes and CVDTwo choices of drugs that reduce CV risk in T2DM
Prof. John Deanfield, MD
- CDMC 2018: Shifting gears in the management of diabetes and CVDLecture: Managing diabetes in daily cardiovascular practice: Potential barriers and solutions
Prof. Richard Hobbs, MD
- CDMC 2018: Shifting gears in the management of diabetes and CVDLecture: Screening for Diabetes: When is it meaningful and how should it be performed
Prof. Lars Rydén
- CDMC 2018: Shifting gears in the management of diabetes and CVDLecture: The GLP1 landscape - refining our understanding
